Albany Molecular Research Inc
AMRI
AMRI was delisted on the 31st of August, 2017.
1 hedge funds and large institutions have $0 invested in Albany Molecular Research Inc in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less capital invested
Capital invested by funds: $112K → $0 (-$112K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCP
Syntal Capital Partners
Midland,
Texas
|
-$112K |
AMRI Hedge Fund Activity: Q4 2019 in Review
1 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q4 2019, worth a combined $0 — down 100% from $112K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of AMRI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Syntal Capital Partners, exiting entirely with an estimated $112K sold.
- 1 institutional investor held Albany Molecular Research Inc (AMRI) as of Q4 2019, down from 2 in Q3 2019.
- Funds reported $0 of Albany Molecular Research Inc stock for Q4 2019, down 100% quarter-over-quarter.
- 0 funds opened new Albany Molecular Research Inc positions in Q4 2019 and 1 closed out, a net change of -1 holder.
- The largest Albany Molecular Research Inc seller in Q4 2019 was Syntal Capital Partners, an estimated $112K sold.
Based on aggregated 13F filings for Q4 2019.